A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

Abstract Background The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in the advanced disease setting. While promising tissue- and plasma-based biomarkers are under in...

Full description

Bibliographic Details
Main Authors: Andrea Botticelli, Massimiliano Salati, Francesca Romana Di Pietro, Lidia Strigari, Bruna Cerbelli, Ilaria Grazia Zizzari, Raffaele Giusti, Marco Mazzotta, Federica Mazzuca, Michela Roberto, Patrizia Vici, Laura Pizzuti, Marianna Nuti, Paolo Marchetti
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Journal of Translational Medicine
Subjects:
Immunotherapy
Lung cancer
Prognostic factors
Nivolumab
Nomogram
Online Access:http://link.springer.com/article/10.1186/s12967-019-1847-x

Internet

http://link.springer.com/article/10.1186/s12967-019-1847-x

Similar Items